US2022211711A1PendingUtilityA1
Methods for treating testicular and ovarian adrenal rest tumors
Est. expiryApr 27, 2038(~11.8 yrs left)· nominal 20-yr term from priority
A61K 9/48A61K 45/06A61K 31/519A61P 5/06A61P 35/00A61K 9/20A61K 9/4841A61K 9/0053A61K 31/5377A61P 5/08A61K 9/2004
76
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided herein are compounds and pharmaceutical compositions for the prevention and treatment of testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART).
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of treating or preventing testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART), comprising administering to a subject in need thereof a compound of Formula (I),
or a pharmaceutically acceptable salt thereof, wherein:
R 1 and R 2 are independently ethyl or n-propyl;
R 3 is hydrogen, Cl, Br, methyl, trifluoromethyl, or methoxy;
R 4 is hydrogen, Br, R a R b N—, methoxymethyl, n-butyl, acetamido, pyridin-4-yl, morpholin-4-yl,
and
R a and R b are independently hydrogen, C 1 -C 3 alkyl, H 2 NCH 2 CH 2 —, (CH 3 ) 3 COC(O)NHCH 2 CH 2 —, or CH 3 CH 2 CH 2 NHCH 2 CH 2 —.
2 . The method of claim 1 , wherein the subject has congenital adrenal hyperplasia (CAH).
3 . The method of claim 1 , wherein the size of the tumors is reduced.
4 . The method of claim 1 , wherein the number of the tumors is decreased.
5 . The method of claim 1 , wherein both the size and the number of the tumors are reduced or decreased.
6 . The method of claim 1 , wherein R 3 is Cl, Br, methyl, or trifluoromethyl.
7 . The method of claim 1 , wherein R 4 is Br, RaR b N—, pyridin-4-yl, morpholin-4-yl, or
8 . The method of claim 1 , wherein R 4 is morpholin-4-yl or
9 . The method of claim 1 , wherein R 4 is hydrogen, Br, R a R b N— and R a and R b are independently C 1 -C 3 alkyl.
10 . The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
11 . The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
12 . The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
13 . The method of claim 1 , wherein the compound, or a pharmaceutically acceptable salt thereof, is administered at a dose of about 5 mg/day to about 100 mg/day to the subject.
14 . The method of claim 1 , wherein the compound, or a pharmaceutically acceptable salt thereof, is administered at a dose of about 10 mg/day to about 400 mg/day to the subject.
15 . The method of claim 1 , wherein the compound, or a pharmaceutically acceptable salt thereof, is administered orally.
16 . The method of claim 1 , wherein the compound, or a pharmaceutically acceptable salt thereof, is formulated as a capsule or tablet.
17 . The method of claim 1 , further comprising administering to the subject an additional chemotherapeutic agent.
18 . The method of claim 17 , wherein the additional chemotherapeutic agent is a glucocorticoid, a mineralocorticoid, an ACAT1 inhibitor, or an anti-androgen.
19 . The method of claim 18 , wherein the glucocorticoid is beclomethasone, betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, or triamcinolone.
20 . A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R 1 and R 2 are independently ethyl or n-propyl;
R 3 is hydrogen, Cl, Br, methyl, trifluoromethyl, or methoxy;
R 4 is hydrogen, Br, R a R b N—, methoxymethyl, n-butyl, acetamido, pyridin-4-yl,
morpholin-4-yl,
R a and R b are independently hydrogen, C 1 -C 3 alkyl, H 2 NCH 2 CH 2 —,
(CH 3 ) 3 COC(O)NHCH 2 CH 2 —, or CH 3 CH 2 CH 2 NHCH 2 CH 2 —.Join the waitlist — get patent alerts
Track US2022211711A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.